Si cierra, no se guardará su personalización salvo que haya añadido el artículo a su carrito de la compra o a favoritos.
Pulse OK para cerrar la herramienta MILLIPLEX® MAP o Cancelar para volver a su selección.
Elija paneles personalizables y kits premezclos - O - MAPmates™ de señalización celular
Diseñe y calcule el precio de sus kits MILLIPLEX® MAP.
Paneles personalizados y kits premezclados
Nuestra amplia cartera de productos consta de paneles multiplex que le permiten elegir, dentro del panel, los analitos que mejor se ajustan a sus requisitos. En una pestaña distinta puede elegir el formato de citocina premezclada o un kit single plex.
Kits de señalización celular y MAPmates™
Elija los kits preparados para poder explorar las vías o los procesos enteros. O diseñe sus propios kits eligiendo single plex MAPmates™ según las directrices proporcionadas.
No deben combinarse los siguientes MAPmates™: -MAPmates™ que requieren un tampón de ensayo diferente. -Pares MAPmate™ fosfoespecíficos y totales, por ejemplo, GSK3β y GSK3β (Ser 9). -MAPmates™ con panTyr y específicos de sitio; por ejemplo, receptor del fosfo-EGF y fosfo-STAT1 (Tyr701). -Más de 1 fosfo-MAPmate™ para una sola diana (Akt, STAT3). -La GAPDH y la β-tubulina no pueden combinarse con kits o MAPmates™ que contengan panTyr.
.
Número de referencia
Descripción para pedidos
Cant./Env.
Lista
Este artículo se ha añadido a favoritos.
Seleccione una especie, un tipo de panel, un kit o un tipo de muestra
Para empezar a diseñar su kit MILLIPLEX® MAP, seleccione una especie, un tipo de panel o un kit de interés.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
Este artículo se ha añadido a favoritos.
Especie
Tipo de panel
Kit seleccionado
Cant.
Número de referencia
Descripción para pedidos
Cant./Env.
Precio de catálogo
96-Well Plate
Cant.
Número de referencia
Descripción para pedidos
Cant./Env.
Precio de catálogo
Añadir más reactivos (Se necesita tampón y un kit de detección para usar con MAPmates)
Cant.
Número de referencia
Descripción para pedidos
Cant./Env.
Precio de catálogo
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Opción para ahorrar espacio Los clientes que adquieran múltiples kits pueden optar por ahorrar espacio de almacenamiento retirando el embalaje del kit y recibiendo los componentes de sus ensayos multiplex en bolsas de plástico para un almacenamiento más compacto.
Este artículo se ha añadido a favoritos.
El producto se ha añadido a su carrito
Ahora puede personalizar otro kit, elegir un kit premezclado, tramitarlo o cerrar la herramienta de pedidos.
1. The present study investigated the role of second messenger-dependent protein kinase A (PKA) and C (PKC) in the regulation of endogenous secretin receptor responsiveness in NG108-15 mouse neuroblastomaxrat glioma hybrid cells. 2. In whole cell cyclic AMP accumulation studies, activation of PKC either by phorbol 12-myristate 13-acetate (PMA) or by purinoceptor stimulation using uridine 5'-triphosphate (UTP) decreased secretin receptor responsiveness. PKC activation also inhibited forskolin-stimulated cyclic AMP accumulation but did not affect cyclic AMP responses mediated by the prostanoid-IP receptor agonist iloprost, or the A(2) adenosine receptor agonist 5'-(N-ethylcarboxamido) adenosine (NECA). 3. In additivity experiments, saturating concentrations of secretin and iloprost were found to be additive in terms of cyclic AMP accumulation, whereas saturating concentrations of NECA and iloprost together were not. This suggests compartmentalization of G(s)-coupling components in NG108-15 cells and possible heterologous regulation of secretin receptor responsiveness at the level of adenylyl cyclase activation. 4. Cells exposed to the PKA inhibitor H-89, exhibited a time-dependent increase in secretin receptor responsiveness compared to control cells. This effect was selective since cyclic AMP responses to forskolin, iloprost and NECA were not affected by H-89 treatment. Furthermore, treatment with the protein synthesis inhibitor cycloheximide produced a time-dependent increase in secretin receptor responsiveness. 5. Together these results indicate that endogenous secretin receptor responsiveness is regulated by PKC, PKA and protein neosynthesis in NG108-15 cells.
Recent epigenomic studies have predicted thousands of potential enhancers in the human genome. However, there has not been systematic characterization of target promoters for these potential enhancers. Using H3K4me2 as a mark for active enhancers, we identified genome-wide EP interactions in human CD4(+) T cells. Among the 6 520 long-distance chromatin interactions, we identify 2 067 enhancers that interact with 1 619 promoters and enhance their expression. These enhancers exist in accessible chromatin regions and are associated with various histone modifications and polymerase II binding. The promoters with interacting enhancers are expressed at higher levels than those without interacting enhancers, and their expression levels are positively correlated with the number of interacting enhancers. Interestingly, interacting promoters are co-expressed in a tissue-specific manner. We also find that chromosomes are organized into multiple levels of interacting domains. Our results define a global view of EP interactions and provide a data set to further understand mechanisms of enhancer targeting and long-range chromatin organization. The Gene Expression Omnibus accession number for the raw and analyzed chromatin interaction data is GSE32677.
Increased glucose flux generates metabolic signals that control transcriptional programs through poorly understood mechanisms. Previously, we demonstrated a necessity in hepatocytes for c-Myc in the regulation of a prototypical glucose-responsive gene, L-type pyruvate kinase (L-PK) (Collier JJ, Doan TT, Daniels MC, Schurr JR, Kolls JK, Scott DK. J Biol Chem 278: 6588-6595, 2003). Pancreatic beta-cells have many features in common with hepatocytes with respect to glucose-regulated gene expression, and in the present study we determined whether c-Myc was required for the L-PK glucose response in insulin-secreting (INS-1)-derived 832/13 cells. Glucose increased c-Myc abundance and association with its heterodimer partner, Max. Manipulations that prevented the formation of a functional c-Myc/Max heterodimer reduced the expression of the L-PK gene. In addition, glucose augmented the binding of carbohydrate response element binding protein (ChREBP), c-Myc, and Max to the promoter of the L-PK gene in situ. The transactivation of ChREBP, but not of c-Myc, was dependent on high glucose concentrations in the contexts of either the L-PK promoter or a heterologous promoter. The glucose-mediated transactivation of ChREBP was independent of mutations that alter phosphorylation sites thought to regulate the cellular location of ChREBP. We conclude that maximal glucose-induced expression of the L-PK gene in INS-1-derived 832/13 cells involves increased c-Myc abundance, recruitment of c-Myc, Max, and ChREBP to the promoter, and a glucose-stimulated increase in ChREBP transactivation.
Previous work in C. elegans has shown that posterior embryonic bodywall muscle lineages are regulated through a genetically defined transcriptional cascade that includes PAL-1/Caudal-mediated activation of muscle-specific transcription factors, including HLH-1/MRF and UNC-120/SRF, which together orchestrate specification and differentiation. Using chromatin immunoprecipitation (ChIP) in embryos, we now demonstrate direct binding of PAL-1 in vivo to an hlh-1 enhancer element. Through mutational analysis of the evolutionarily conserved sequences within this enhancer, we identify two cis-acting elements and their associated transacting factors (PAL-1 and HLH-1) that are crucial for the temporal-spatial expression of hlh-1 and proper myogenesis. Our data demonstrate that hlh-1 is indeed a direct target of PAL-1 in the posterior embryonic C. elegans muscle lineages, defining a novel in vivo binding site for this crucial developmental regulator. We find that the same enhancer element is also a target of HLH-1 positive auto regulation, underlying (at least in part) the sustained high levels of CeMyoD in bodywall muscle throughout development. Together, these results provide a molecular framework for the gene regulatory network activating the muscle module during embryogenesis.